by Barry101 | Jun 27, 2023 | Press Release
Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient enrollment expected to commence before the end of 2023 OCALA, Fla., June 27, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM)...
by Barry101 | Jun 14, 2023 | Press Release
Live webcast fireside chat on Wednesday, June 21st at 12:00 PM ETOCALA, Fla., June 14, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of...
by Barry101 | Jun 12, 2023 | Press Release
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the treatment of pancreatic cancer (AMP-270) Ongoing progress toward...
by Barry101 | May 15, 2023 | Press Release
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023- Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter...
by Barry101 | May 9, 2023 | Press Release
OCALA, Fla., May 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and...
